AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02873806
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) .
Trial: NCT03359811
Drug: Local Anesthetic Solution
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
Trial: NCT05106101
Drug: L-glutamine
RxNorm normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine oral powder in 5 gram packet
Trial: NCT03011931
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
Trial: NCT03980054
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 400mg, orally once daily for one year
Trial: NCT03959891
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.
Trial: NCT00578331
Drug: Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sprays each nostril twice daily
Trial: NCT04859738
Drug: Benzokain Sprey
RxNorm normalized name: benzocaine Oral Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Benzocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter will be applied to the patients in the Experiment II Group (Benzocaine Spray). After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse.
Trial: NCT03081858
Drug: TSD-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via intravesical instillation.
Trial: NCT00000385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02130817
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
Trial: NCT03755258
Drug: GCK 100 mg + Placebo 200 mg
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCK 100 mg + Placebo 200 mg, oral, 12 weeks
Trial: NCT03755258
Drug: GCK 200 mg + Placebo 100 mg
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCK 200 mg + Placebo 100 mg, oral, 12 weeks
Trial: NCT03755258
Drug: GCK 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCK 300 mg, oral, 12 weeks
Trial: NCT03755258
Drug: Placebo 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 300mg, oral, 12 weeks
Trial: NCT00830882
Drug: racemic salbutamol
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs four times a day for 2 weeks
Trial: NCT00830882
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs four times a day for 2 weeks
Trial: NCT00495313
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COL-101, QD plus metronidazole
Trial: NCT00495313
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg with metronidazole QD
Trial: NCT01213888
Drug: Oral placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
Trial: NCT04508504
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL 0.9% Normal saline will be injected for the Placebo block
Trial: NCT01864746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
Trial: NCT04563845
Drug: GSK3640254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 will be administered.
Trial: NCT04563845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT02351622
Drug: Caffeic acid
RxNorm normalized name: CAFFEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of caffeic acid tablet 0.3g three times per day for 1 year
Trial: NCT02351622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
Trial: NCT01484119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets and capsules
Trial: NCT01982942
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
Trial: NCT02185040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo daily
Trial: NCT01667731
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Trial: NCT03398759
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection during induction
Trial: NCT00816712
Drug: Comparator: Testosterone 300 mg, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 300 mg, Intramuscular injection.
Trial: NCT00816712
Drug: Comparator: Testosterone 100 mg, Intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 \& 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 100 mg, Intramuscular injection.
Trial: NCT00816712
Drug: Comparator: Placebo given by Intramuscular Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Placebo given as intramuscular injection.
Trial: NCT00402376
Drug: Pravastatin, Carvedilol, Perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02345070
Drug: SAR156597
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Trial: NCT02345070
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Trial: NCT01880320
Drug: CD0271 0.3% / CD1579 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01880320
Drug: CD0271 0.1% / CD1579 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02217020
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Trial: NCT02530580
Drug: 20 mg AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 20 mg oral dose of AZD7325
Trial: NCT02530580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose
Trial: NCT04656262
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
Trial: NCT04656262
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
Trial: NCT00003524
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT03858621
Drug: fentanyl NOL guided
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
Trial: NCT03143465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03741257
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: resuscitation fluid
Trial: NCT02263976
Drug: BEA 2180 BR
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02263976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02263976
Drug: Methacholine Chloride
RxNorm normalized name: Methacholine Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methacholine challenge test
Trial: NCT03938857
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl standard of care
Trial: NCT00321620
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
Trial: NCT02406586
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salsalate 750 mg
Trial: NCT02406586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet
Trial: NCT01287962
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po，QD； 28 days every cycle
Trial: NCT00962624
Drug: meningococcal B vaccine & meningococcal ACYW conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
Trial: NCT01384513
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03928184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare professional-administered intra-articular injection; performed on Day 1
Trial: NCT01815918
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
Trial: NCT01815918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
Trial: NCT00615303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
Trial: NCT00511602
Drug: Technosphere Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere Inhalation Powder
Trial: NCT04325490
Drug: Liquid powder
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
Trial: NCT01072175
Drug: GSK2118436
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
Trial: NCT01072175
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
Trial: NCT02643420
Drug: SPI-2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
Trial: NCT02643420
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard therapy
Trial: NCT04154072
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (Sodium Chloride)
Trial: NCT02649673
Drug: Pegylated GCSF (PEG-GCSF)
RxNorm normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
Trial: NCT02194335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00682539
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
Trial: NCT03737812
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for infusion
Trial: NCT04470154
Drug: Stage I:HSK21542 0.05 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Trial: NCT04470154
Drug: Stage I:HSK21542 0.15 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Trial: NCT04470154
Drug: Stage I:HSK21542 0.30 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Trial: NCT04470154
Drug: Stage I:HSK21542 0.80 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
Trial: NCT04470154
Drug: Stage II:HSK21542 0.3 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
Trial: NCT04470154
Drug: Stage II:HSK21542 0.6 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
Trial: NCT01418066
Drug: Placebo tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
Trial: NCT03165227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally
Trial: NCT03854578
Drug: Placebo matching BI 1358894
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT02702076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of placebo during waking day
Trial: NCT00672464
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
Trial: NCT03249259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
Trial: NCT00439920
Drug: High-dose anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00267202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
Trial: NCT00267202
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours.
Trial: NCT02778594
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebicapone 50 mg tablets; oral use
Trial: NCT02778594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebicapone matching placebo tablets
Trial: NCT02778594
Drug: levodopa 100 mg / benserazide 25 mg
RxNorm normalized name: levodopa 100 MG / benserazide 25 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
Trial: NCT04499118
Drug: AT regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
Trial: NCT04499118
Drug: TP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
Trial: NCT00563056
Drug: Flutiform
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00563056
Drug: Flixotide plus Foradil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00434317
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03343912
Drug: Estriol 0.400 mg/day and Trimegestone 0.06 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application
Trial: NCT03343912
Drug: Estriol 0.300 mg/day and Trimegestone 0.12 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application
Trial: NCT03343912
Drug: Estriol 0.200 mg/day and Trimegestone 0.18 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application
Trial: NCT01253278
Drug: LY2393910
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as capsules, administered orally once daily for two weeks
Trial: NCT01253278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as capsules, administered orally once daily for two weeks
Trial: NCT02357654
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo